Clinical Trial Update: Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

View source ↗

Summary

A real-world study from Hebei Medical University Fourth Hospital evaluating neratinib as extended adjuvant therapy for patients with HER2-positive early breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: HER2-positive Breast Cancer | Status: NOT_YET_RECRUITING